 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Oral, eye drops |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 20% |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.050.071 |
| Chemical and physical data | |
| Formula | C14H12O3S |
| Molar mass | 260.31 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Suprofen is anonsteroidal anti-inflammatory drug (NSAID) developed byJanssen Pharmaceutica[1] that was marketed as 1% eye drops under thetrade nameProfenal.
Suprofen was originally used astablet, but oral uses have been discontinued due torenal effects.[2] It was subsequently used exclusively as atopicalophthalmic solution, typically to preventmiosis during and after ophthalmicsurgery.[3] This application has been discontinued as well, at least in the US.[4]
{{cite book}}:|journal= ignored (help)CS1 maint: DOI inactive as of July 2025 (link)| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key:underline indicates initially developed first-in-class compound of specific group;#WHO-Essential Medicines;†withdrawn drugs;‡veterinary use. | |
 | Thisdrug article relating to themusculoskeletal system is astub. You can help Wikipedia byexpanding it. |
